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Abstract
Objectives: Defining clinically relevant outcome measures for myotonic dystro-
phy type 1 (DM1) that can be valid and feasible for different phenotypes has
proven problematic. The Outcome Measures for Myotonic Dystrophy
(OMMYD) group proposed a battery of functional outcomes: 6-minute walk
test, 30 seconds sit and stand test, timed 10 m walk test, timed 10 m walk/run
test, and nine-hole peg test. This, however, required a large-scale investigation,
Methods: A cohort of 213 patients enrolled in the natural history study, Phe-
noDM1, was analyzed in cross-sectional analysis and subsequently 98 patients
were followed for longitudinal analysis. We aimed to assess: (1) feasibility and
best practice; (2) intra-session reliability; (3) validity; and (4) behavior over
time, of these tests. Results: OMMYD outcomes proved feasible as 96% of the
participants completed at least one trial for all tests and more than half
(n = 113) performed all three trials of each test. Body mass index and disease
severity associate with functional capacity. There was a significant difference
between the first and second trials of each test. There was a moderate to strong
correlation between these functional outcomes and muscle strength, disease
severity and patient-reported outcomes. All outcomes after 1 year detected a
change in functional capacity except the nine-hole peg test. Conclusions: These
tests can be used as a battery of outcomes or independently based on the
shown overlapping psychometric features and strong cross-correlations. Due to
the large and heterogeneous sample of this study, these results can serve as ref-
erence values for future studies.
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Introduction
Myotonic dystrophy type 1 (DM1) characterizes as a slow
and progressive condition with marked multisystem vari-
ability. It is the second most common form of inherited
muscular dystrophy and the most common among
adults.1–3 An expansion of CTG-repeats in the DNA is
the cause behind it and directly correlates to age of onset
and disease severity.4 DM1 typically presents with muscle
wasting and weakness combined with “myotonia” and
additional symptoms that culminate in impaired perfor-
mance in tasks of everyday life.5,6 Potential treatments
have emerged in the last decade requiring the establish-
ment of the best methods to measure disease progression
and therapeutic impact.7–9 However, due to the nature of
the disease and its heterogeneous phenotypes understand-
ing and monitoring clinical progression has been a chal-
lenging task.9,10
Differences between adult-onset and late-onset pheno-
types have been reported before.11–16 In addition, func-
tional performance can differ due to age, gender, and
body composition as reported not only in DM1 but also
in healthy populations and other neurological disorder.17–
21 This should be considered when designing clinical trials
in DM1.
Outcome measures for myotonic dystrophy
The international outcome measures for myotonic dystro-
phy (OMMYD) project was launched in 2011 with the
aim of selecting the best available outcome measures to
be used in research and clinical trials in DM1.22,23 In the
case of the functional capacity outcome measures
(FCOM), the first step consisted of reviewing existing
tests that could assess disease domains related to func-
tional capacity. This was accomplished through a system-
atic literature review of tools previously used in DM1 or
other diseases with similar characteristics.22 A second
meeting 2 years later refined the previously selected out-
comes based on three criteria: feasibility, validity, and dis-
crimination (i.e., sensitivity and specificity to discriminate
disease stages I–III and IV–V of the Muscular Impairment
Rating Scale – MIRS).23,24 The third and final meeting
resulted in consensus of the FCOM tests and recom-
mended procedures to follow when implementing these
in DM1 trials.25
The battery of FCOM tests include: (1) 6-minute walk
test (6MWT), (2) timed 10 m walk test (10mWT) (i.e.,
walking at comfortable speed) and timed 10 m walk/run
test (10mW/RT) (i.e., walking/running at maximum
speed); (3) 30 seconds sit and stand test (30SSS), and (4)
nine-hole peg test (9HPT).22,23,25 Prior to this project, the
6MWT, 10mWT at comfortable speed, the10mWT at
maximum speed and the 9HPT have undergone more rig-
orous testing assessing feasibility and/or reliability in
adults with DM1.26–28 Longitudinal data in relatively
small samples have been published for the 6MWT29 and
the 10mWT at maximum speed.13 These findings com-
bined highlighted the need for a large-scale study imple-
menting standardized procedures that would facilitate
generalizability of results and to provide evidence-based
guidelines to improve reliability.
As part of the PHENODM1 natural history study and
following up from the OMMYD work, we investigated
FCOM tests more thoroughly and in a much larger
patient sample. The aim of this cross-sectional (n = 213)
and longitudinal (n = 98) study was to explore the use of
outcome measures that assess functional capacity in
adults with DM1 that maybe suitable for use in clinical
trials. We aimed to analyze the following: (1) feasibility
and best practice for clinical trials; (2) intra-session relia-
bility; (3) validity, that is, association between FCOM
tests and measures of muscle strength, disease severity
(i.e., MIRS and Scale for Assessment and Rating of Ataxia
[SARA]30), and, patients’ perceived functional perfor-
mance; and (4) describe changes in the cohort after
1 year of natural disease progression as assessed by these
FCOM. In addition, as part of the initial analysis, we
aimed to investigate the degree in which demographic
characteristics may affect the performance of the FCOM
tests.
Methods
Study design
This study forms part of the observational natural history
PHENODM1 study (ClinicalTrials.gov Identifier:
NCT02831504). PHENODM1 is a multicenter study (i.e.,
The Newcastle upon Tyne Hospitals NHS Foundation
Trust, and University College Hospitals NHS Foundation
Trust in London) aiming to deeply phenotype an adult
DM1 population to support the design of future clinical
trials. This research was approved by The Newcastle and
North Tyneside Ethics committee (Reference: NE/15/
0178).
Sample
A sample of 213 patients were recruited in both sites fol-
lowing a non-probability strategy between October 2015
and February 2017 and included for baseline cross-sec-
tional analysis. The inclusion criteria were: a genetically
confirmed diagnosis of DM1; ≥18 years; ability to provide
informed consent and walk independently (assistive
devices and orthotics allowed) for at least 10 m. The
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cohort recruited at one of the study sites (Newcastle) was
followed up for 1 year as part of the longitudinal analysis.
Patients were classified as late onset if they met two of
the three following criteria: (1) first symptoms reported
at the age of ≥40 years; (2) ≤200 CTG repeats; and (3) a
MIRS score of I or II; otherwise they were categorized as
adult (classic) phenotype.15,16,31 Participants with an early
adult (juvenile) phenotype (i.e., first symptoms reported
before 20 years old) were included in the adult phenotype
group. There was a low possibility for congenital pheno-
types (i.e., cognitively more severely impaired) to be
recruited as participants should be competent to provide
informed consent and considered suitable to complete all
study questionnaires.
Procedures
This study focused on the exploration of the OMMYD
FCOM tests: (1) 6MWT; (2) 10mWT; referring walking at
comfortable speed (i.e., patient’s selected pace); (3) 10mW/
RT, referring to walking at the maximum possible and safe
speed, allowing running if possible; (4) 30SSS; and (5)
9HPT.22,23,25 The following outcomes were considered for
cross comparisons at baseline: (1) demographic character-
istics (i.e., age, sex, age since disease onset, CTG mode at
baseline, height, and weight); (2) muscle strength and
capacity including: quantitative muscle testing (QMT) of
ankle dorsiflexion, knee extension, and hip flexion follow-
ing standardized procedures and using Microfet2 and
including the best out of three attempts for analysis15; (3)
the MIRS which is a five-categories classification method
for assessing disease progression as measured by muscle
weakness manifestations and manual muscle testing24; (4)
SARA scale which assess movement co-ordination and has
been reported as possible assessment of disease severity in
DM1 regardless of the presence of ataxia or not30; and (5)
disease-specific patient-reported outcome measures
(PROM) that assess perceived functional performance
which included the DM1-ActivC Rasch built scale and the
Myotonic Dystrophy Health Index (MDHI) subscales of
ability to perform activities and mobility.32–35
Functional tests were assessed in a pre-specified sequen-
tial order: (1st) 6MWT (only one trial); (2nd) 30SSS;
(3rd) 10mWT; and (4th) 10mW/RT. These last three tests
were requested three times (i.e., trials) as considered pos-
sible. Time for recovery in sitting position was allowed
between tests. Results are reported as an average and best
(i.e., fastest or highest) score. The 9HPT was performed
twice per hand side. For the purposes of this manuscript,
scores from the dominant side were selected. The
methodology followed when testing these FCOM tests has
been published as part of the OMMYD-3 report.25
The10mWT and 10mW/RT standard operation
procedures developed for this study differed from the
ones established in the OMMYD-3 report allowing a 1-m
flying start before initiating the stopwatch.
Statistical analysis
IBM SPSS Statistics version 24 and R version 3.5.0 were
used for all the presented analysis. Statistical analyses are
outlined in depth in Data S1.
Results
Two hundred and thirteen (n = 213) participants were
screened between both sites with a similar distribution of
men and women. Thirteen percent of the participants
reported wheelchair use in daily life and 172 were classi-
fied as “adult phenotype,” The majority of our sample
(81%) presented a MIRS score between II and IV, and
the most commonly reported limitation to perform at
least one of the FCOM tests was “poor neuromuscular
control” (including issues like: impaired balance, muscle
weakness, or movement disorders). Baseline demographics
and clinical characteristics are summarized in Table 1.
Figure 1 presents violin plots for each of the FCOM tests
stratified by sex and differentiated based on disease pheno-
type (i.e., adult and late onset). Statistically significant dif-
ferences between genders were identified for all assessments
except for SARA score (P = 0.42) and 30SSS (P = 0.15).
Body mass index (BMI) demonstrated significant impact
on FCOM tests scores when incorporated into multivariate
regression models, with gender also significantly influenc-
ing 9HPT. MIRS was also a highly significant factor across
all FCOM tests scores. When MIRS was excluded from the
model, disease phenotype was significant for all tests scores.
Replacing MIRS with CTG-repeat count in the model
showed significance in three FCOM tests (6MWT, SARA,
and 30SSS) but also resulted in a loss of significance of
BMI and phenotype group. Age was not a significant vari-
able influencing between subgroup differences.
Table S1 provides a full description of results classified
by MIRS score and disease phenotype. Overall, MIRS
classification showed a decline in performance from better
scores (i.e., median) presented in the higher ranking of
the MIRS (i.e., I and II) to worse in the lower ranks of
the MIRS. This was observed in all tested outcomes.
Phenotype subgroups differed between each other signifi-
cantly in all FCOM scores, with the exception of the
9HPT in the female subgroup (Table S1).
Feasibility and best practice
The percentage (%) of participants completing each trial
per FCOM tests (10mWT, 10mWT/RT, 30SSS, and
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9HPT) and the trial in which they scored their best are
presented in Figure 2. More than 80% of the partici-
pants performed at least a second trial and over 50%
completed three trials in those tests required. Over 60%
of the participants performed their best on their first or
second trial. With the exception of the 10mWT, the
most common reason (80%) not to carry out a second
or third trial was fatigue followed by fear of falling from
either the examiners’ or participants’ point of view. In
the case of the 10mWT the most common reason not
to repeat was consistency between the first and second
trials as judged by the assessor. In the case of the 30SSS
and the 10mW/RT participants with a milder presenta-
tion of the disease (i.e., MIRS I and II) scored better at
the second or third trial. The majority (62%) of partici-
pants with a more severe presentation (i.e., MIRS V)
scored their best at the first attempt. Twenty patients
(9%) were not able to perform the 30SSS test without
support so their best and only score considered was
recorded as “zero times.” Three falls were reported for
the 6MWT and two for the 10mW/RT although only
one of these resulted in stopping the test (i.e., 6MWT)
with no resultant injuries.
Intra-session reliability
All FCOM tests performed more than once showed high
intraclass correlation coefficients (ICC2,1): 10mWT
(ICC = 0.99, 95% confidence interval [CI] 0.99–0.99);
10mW/RT (ICC = 0.99, 95% CI 0.98–0.99); 30SSS
(ICC = 0.96, 95% CI 0.89–0.98); and 9HPT (ICC = 0.90,
95% CI 0.83–9.94). There was a statistically significant
difference (P < 0.001) from the first trial to the second
on all FCOM tests and between the second and third tri-
als only for the 30SSS (Fig. 2). Bland-Altman plots
between the second and the third trials of the 10mWT
and 10mW/RT confirmed an absolute agreement between
these trials (mean difference of 0.5 sec and a 95% limit of
agreement between 2.0 and 2.1 sec). There was a signifi-
cant difference (P = 0.004) between the 9HPT completed
with the dominant side and the non-dominant side of
1.2 sec (standard deviation [SD] 6.7 sec) (Table S1).
Construct validity
There were significant correlations between most FCOM
tests (average scores), and measures of muscle strength
Table 1. Sample demographics presenting mean and standard deviation (SD) or number (n) and percentage (%), and subgroups comparison.
All Male Female Significant
between groupsN 213 104 109
Mean  SD Mean  SD Mean  SD
Age (years) 45.2  14.5 47.2  14.5) 43.2  13.9 0.05
Height (m) 1.7  0.1 1.8  0.08 1.6  0.07 <0.001
BMI 26.2  5.9 25.9  5.6 26.4  6.3 0.06
Years with active education 14.9  3.1 15.4  3.5 14.3  2.6 0.03
Years since first recalled symptoms 19.8  13.6 18.1  15.3 21.2  12 ns
Phenotype n (%) n (%) n (%)
Late onset 41 (19) 24 (23) 17 (16) ns
MIRS 0.06
I: no muscular impairment 22 (10) 15 (14) 7 (6)
II: minimal signs of muscular impairment 59 (28) 23 (22) 36 (33)
III: distal weakness 46 (22) 26 (25) 20 (18)
IV: mild proximal weakness 70 (32) 30 (28) 40 (36)
V: severe proximal weakness 16 (8) 10 (10) 6 (6)
Walking accessories ns
Missing data 3 (1) 0 3 (3)
None 178 (84) 87 (84) 91 (83)
Cane 27 (13) 14 (13) 13 (12)
Crutches 3 (1) 2 (2) 1 (1)
Walker 2 (2) 1 (1) 1 (1)
Reported wheelchair use in daily life 27 (13) 11 (11) 16 (15) ns
Reported capability to run ns
Missing data 4 (2) 1 (1) 3 (3)
Not possible 79 (37) 40 (38) 39 (36)
Possible with difficulty 56 (26) 24 (23) 32 (29)
Possible with no difficulty 74 (65) 39 (38) 35 (32)
ns, not significant (i.e., >0.05). BMI, body mass index; MIRS, muscular impairment rating scale.
4 ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
OMMYD Functional Outcomes for Myotonic Dystrophy A. C. Jimenez-Moreno et al.
0250
500
750
male female
Sex
Si
x 
M
in
ut
e 
W
al
k 
Te
st
A
0
10
20
30
40
male female
Sex
Ti
m
ed
 1
0 
M
et
re
 W
al
k 
Te
st
B
0
10
20
male female
Sex
Ti
m
ed
 1
0 
M
et
re
 W
al
k/
R
un
 T
es
t C
0
50
100
150
male female
Sex
N
in
e−
H
ol
e 
Pe
g 
Te
st
D
0
10
20
30
40
male female
Sex
30
 S
ec
on
ds
 S
it 
to
 S
ta
nd
 T
es
tE
0
10
20
male female
Sex
SA
R
A
F
Figure 1. Violin plots. This figure represents the results obtained for each functional capactity outcome measure (A-E) and the SARA (F) stratified
by sex and identified by disease phenotype. These violin plots are a combination of a box plot (median, interquartile range, and adjacent values)
and a density of data distribution plot. Black color represents the distribution of results corresponding to the adult phenotype and red color
represents results corresponding to the late-onset phenotype.
Figure 2. Trial completion and performance chart. This bar chart presents the percentage of participants completing each trial and the
percentage performing their best at each trial (from those completing the test). **Average scores from test to test changed with a significance
<0.01 (paired t-test). ***Average scores from test to test changed with a significance <0.001 (paired t-test). If two trials scored equally, the first
trial was consider as the best trial. ^20 patients (9%) were not able to perform the 30SSS test so their best and only score considered was “zero
times.” b31% of the whole sample completed at least two trials with the same score (times). #13% of the whole sample completed both trials
with the same score (seconds).
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(QMT), SARA score, and the PROMs results (Table 2).
Less than moderate correlations (i.e., correlation coeffi-
cient <0.5) were mainly found between the FCOM tests
and measures of muscle strength, whereas correlations
with the SARA were all in the moderate range (i.e., corre-
lation coefficients ≥0.5) and correlations with the PROMs
were all in the moderate to strong range (i.e., between 0.5
and 0.9) except for the 9HPT (i.e., <0.5). The 30SSS test
showed a significant correlation with MDHI-fatigue sub-
scale, which is not presented in this table (r = 0.5,
P < 0.01). There was a strong correlation (r = 0.8,
P < 0.01) identified between the walking capacity tests
(i.e., 6MWT, 10mWT, and 10mW/RT) (data not pre-
sented in table).
Longitudinal analysis
From 110 patients screened in Newcastle, 98 completed a
second follow-up visit 12 months apart. From the 12
losses in follow-up, 10 were study dropouts or failures to
attend within visit window and two were due to serious
events not related to the study. Demographics at baseline
and the mean and SD of those patients’ scores at baseline
(T1) and follow-up visit (T2) are presented in Table 3 as
a whole sample and in Table 4 divided by disease-pheno-
type subgroups. There was a clear distinction in disease
phenotype between adult and late-onset subgroups with
all parameters showing a statistically significant difference
at baseline (T1). With the exception of the 9HPT, all
FCOM tests showed statistical significant changes over
time, as did SARA. This significant decline was not
detected with muscle strength assessments, nor with QMT
nor MIRS (Fig. 3). Both phenotype subgroups showed
similar and significant changes over time. The adult phe-
notype subgroup showed a statistically significant change
(of improvement) in muscle strength scores which was
not observed in the late-onset subgroup. Patients that
scored a MIRS of III and IV at baseline also showed vari-
ability (of improvement) at follow-up (Fig. 3).
Discussion
Assessing functional capacity in people with DM1 is
essential to monitor natural disease progression and the
possible effect of any intervention. This study explores
feasibility, intra-session reliability, validity, and sensitivity
to detect change of the OMMYD suggested FCOM tests
for the first time after the establishment of the OMMYD
FCOM guidelines.25
Significant differences in performance scores were
observed between genders (due to body composition dif-
ferences and muscle strength) with men commonly scor-
ing higher than women. In DM1, however, it has been
reported that men more frequently have muscular weak-
ness and disability which at first glance would not be
reflected on the overall scores of these FCOM tests.11
However, when comparing the differences between sub-
groups and controlling for variables expected to impact
on these scores (i.e., age, height, BMI, MIRS and CTG-re-
peats mode at baseline), the significance between sub-
groups comparison changed (Table S1). For example,
after performing this model, walking tests (i.e., 6MWT
and 10mWT) significance between male and female disap-
peared and the difference in 30SSS became significant
highlighting the relevant influence of BMI and MIRS in
these scores. The late-onset phenotype subgroup differed
significantly from the adult phenotype in all outcomes,
which proves once more that generalizability of results
should be cautious when considering data from mixed-
phenotypic samples and the association with muscular
strength as measured by MIRS.11–16 However, using five
categories of disease severity (i.e., MIRS) as compared to
only two (i.e., Phenotype) was shown to be more strongly
associated with patient performance. SARA scores were
not influenced by age, sex or height, making it a suitable
outcome for wider comparisons.
Mean values obtained on these FCOM tests are compa-
rable to other relevant adult neurological conditions.36,37
Normative data for 30SSS for an adult establishes scores
Table 2. Correlation scores between outcome measures.1
Outcome
measure SARA
Knee extensors
QMT
Hip flexors
QMT
Ankle dorsi-flexors
QMT
MDHI -ability to
perform activities subscale
MDHI -mobility
subscale
DM1-ActivC
TOTAL score
6MWT ()0.65 0.47 0.51 0.45 ()0.64 ()0.73 0.69
10mWT 0.65 ()0.36 ()0.45 ()0.43 0.63 0.73 ()0.67
10mW/RT 0.55 ()0.32 ()0.51 ()0.47 0.58 0.66 ()0.59
30SSS ()0.67 0.44 0.53 0.52 ()0.58 ()0.65 0.65
9HPT 0.55 ns ns ()0.26 0.23 0.32 ()0.41
Outcome measure: 6MWT (6-minute walk test), 10mWT (timed 10 m walk test), 10mW/RT (timed 10 m walk/run test), 30SSS (30 sec sit and
stand test), and 9HPT (nine-hole peg test). SARA, scale for assessment and rating of ataxia; QMT, quantitative muscle testing (best score of three);
MDHI, Myotonic Dystrophy Health Index; DM1, myotonic dystrophy type 1.
1All correlations presented showed to be significant at the <0.01 level (two tailed).
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from 13 to 15 full stands (i.e., repetitions) for women
and from 14 to 17 full stands for men.38,39 In our popula-
tion only participants completing a third trial of the test
accomplished these scores and these participants were
generally the least affected (i.e., MIRS I, II, and III). In
fact, the average score obtained as a group on the first
trial was below the cut-off value predicted for a popula-
tion between 60 and 70 years old.39,40
We identified that when assessing functional outcomes
(i.e., 10mWT, 6MWT, timed-stands test, and the timed
up-and-go test) in DM1, at least half of the participants
performed their best test at either the second or the third
trial.41 Based on the resulting intra-session ICC2,1 and the
non-difference detected between the second and the third
trial observed for the 10mWT and the 10mW/RT we sug-
gest that two trials of these tests will be sufficient to pro-
vide a valid and reliable score. Still, due to the significant
change from the first to the second trials, there seems to
be a learning effect that should be considered. In addi-
tion, it is feasible to perform these tests at least once all
together as 96% of the participants completed all five
FCOM tests, 6MWT inclusive. However, as expected, not
all participants were able to complete all assessments three
times. Fear of falling was the most common reason for
failure to complete (Fig. 2). The 30SSS, had the lowest
compliance rate; however, the more trials that were com-
pleted, the greater chance participants had to perform
their best trial. This improvement was seen for partici-
pants with MIRS I to III. In this test, the reduced compli-
ance was mostly attributed to fatigue which concurs with
what has been suggested before for this test39,42 but also
correlated with the MDHI-fatigue score (r = 0.5,
P < 0.01). Due to disease-associated limiting factors such
as fatigue, pain, and poor balance, an exhaustive examina-
tion of these patients is discouraged and a careful consid-
eration to reduce the number of assessments or visit
length is recommended. The 10mWT and 10mW/RT are
tests relatively short in time, making them more feasible
for trial repetition and when compared to the 6MWT; all
three assess walking capacity and demonstrated strong
correlation between each other. Due to the observed vari-
ability from trial to trial, using the “best” trial for analysis
Table 3. Longitudinal (12 months) data.
All (adult and late-onset phenotype)
(T1)
(T2)
Mean (SD) Mean change Percentage Lower CI to upper CI Level of significance
Demographics
N= 98
Females (n) 43 (44%)
Age (years) 46 (14)
Height (m) 2 (6)
BMI 26 (6)
Late-onset phenotype (n) 22 (23%)
Progenitor allele (CTG count) 256 (184)
CTG mode (CTG count) 500 (357) 3.8 1% 7.4–15 ns
Outcome measures
6MWT (m) 425 (94) 35.3 8% 21.1 to 49.6 <0.001
10mWT (sec) – average 9.6 (4.3) 1.1 11% 1.8–0.3 0.004
10mWT (sec) – best 9.2 (4.2) 1.2 13% 1.9–0.4 0.002
10mW/RT (sec) – average 5.3 (3.0) 0.8 15% 1.3–0.3 0.003
10mW/RT (sec) – best 5.0 (3.0) 0.9 18% 1.5–0.3 0.002
30SSS (times) – average 11.2 (5.8) 0.7 6% 0.1 to 1.3 0.03
30SSS (times) – best 12.1 (6.3) 1.2 10% 0.5 to 1.8 0.001
9HPT (sec) – average 27.7 (13.7) 0.7 3% 2.9 to 1.4 ns
9HPT (sec) – best 25.7 (12.4) 0.9 4% 3.1 to 1.2 ns
SARA (score) 6.1 (4.9) 1.1 18% 1.7–0.5 0.001
Knee extensors QMT (lb) 46.4 (19.4) 2.1 5% 5.4 to 1.1 ns
Hip flexors QMT (lb) 33.7 (13.1) 2.2 6% 4.8 to 0.5 ns
Ankle dorsi-flexors QMT (lb) 25.6 (13.3) 1.9 7% 4.5 to 0.7 ns
Results at baseline (T1) are presented as mean and standard deviation (SD) and changes over time are presented (T2) as mean change and 95%
confidence intervals (CI). Outcome Measure: 6MWT (6-minute walk test), 10mWT (timed 10 m walk test), 10mW/RT (timed 10 m walk/run test),
30SSS (30 sec sit and stand test), 9HPT (nine-hole peg test), and SARA (scale for assessment and rating of ataxia). BMI, body mass index; QMT,
quantitative muscle testing (best score of three).
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 7
A. C. Jimenez-Moreno et al. OMMYD Functional Outcomes for Myotonic Dystrophy
would risk ignoring the natural variation of the test,
whereas the average of repeated trials may be more repre-
sentative of a true score.43
Our results provide evidence of the association of these
FCOM tests with muscle strength and the SARA assess-
ments as surrogates of disease severity. Twenty-five per-
cent of the performance to walk and to stand up from a
chair can be explained by muscle strength.13,26,27,44,45 The
6MWT and 10mWT maintain similar correlation trends
among all tests. Once more, knee extensors and ankle
dorsiflexors strength have shown significant impact on
test performance.13,27 The minimal correlation identified
between 9HPT and ankle dorsiflexion has not been con-
sidered relevant assuming this as a spurious finding.
With the exception of 9HPT, all FCOM tests and SARA
showed a statistically significant change after 1 year in this
large and heterogeneous study population. Still, the clinical
significance and impact on disease burden of these changes
needs further investigation. QMT muscle testing and MIRS
scores did not show an overall significant change but even
Table 4. Longitudinal (12 months) data.
Adult phenotype Late-onset phenotype
(T1) (T2) (T1) (T2)
Mean
(SD)
Mean
change Percentage
Lower CI
to upper
CI
Level of
significance
Mean
(SD)
Mean
change Percentage
Lower CI
to upper
CI
Level of
significance
Demographics
N = 76 22
Females (n) 33 (43%) 10 (45%)
Age (years) 43 (13) 57 (13)
Height (m) 2 (10) 2 (9)
BMI 26 (6) 25 (4)
Outcome measures
6MWT (m) 381 (153) 36.2 10% (19.3
to
53.1)
<0.001 588 (94) 32.0 5% (5.8 to
58.2)
0.02
10mWT (sec) –
average
10.3 (4.6) 1.3 12% (2.2–0.3) 0.009 7.2 (1.3) 0.4 6% (0.8–0.0) 0.04
10mWT (sec) –
best
9.9 (4.5) 1.4 14% (2.3–0.4) 0.004 6.9 (1.3) 0.4 6% (0.8–0.1) 0.03
10mW/RT (sec)
– average
6.0 (3.2) 0.9 14% (1.5–0.2) 0.01 3.3 (1.3) 0.6 18% (1.1–0.1) 0.02
10mW/RT (sec)
– best
5.6 (3.1) 0.9 17% (1.6–0.2) 0.01 2.9 (1.3) 0.8 28% (1.3–0.3) 0.004
30SSS (times) –
average
10.1 (5.4) 0.6 6% (0.2 to
1.3)
ns 15 (5.7) 1.1 7% (0.2 to
2.0)
0.02
30SSS (times) –
best
11 (5.8) 1.0 10% (0.2 to
1.8)
0.01 16.1 (5.8) 1.6 10% (0.6 to
2.5)
0.002
9HPT (sec) –
average
29.6 (15) 1.0 3% (3.8 to
1.7)
ns 21.3 (2.7) 0.2 1% (0.9 to
1.3)
ns
9HPT (sec) –
best
27.1 (14) 1.4 5% (4.2 to
1.4)
ns 20.7 (2.7) 0.6 3% (0.6 to
1.9)
ns
SARA (score) 7.5 (4.8) 1.1 15% (1.9–0.3) 0.01 2 (4.9) 1.1 55% (2.1–0.1) 0.04
Knee extensors
QMT (lb)
44.2 (19) 1.1 2% (4.4 to
2.2)
ns 54.3 (19.1) 5.8 11% (15.6 to
4.0)
ns
Hip flexors
QMT (lb)
31.6 (14) 3.3 10% (6.3–0.3) 0.03 37.3 (12) 1.9 5% (4.0 to
7.7)
ns
Ankle dorsi-
flexors QMT
(lb)
21.6 (12) 3.5 16% (6.3–0.6) 0.02 33.3 (15.4) 2.2 7% (3.3 to
7.7)
ns
Results at baseline (T1) are presented as mean and standard deviation (SD) and changes over time are presented (T2) as mean change and 95%
confidence intervals (CI). Outcome Measure: 6MWT (6-minute walk test), 10mWT (timed 10 m walk test), 10mW/RT (timed 10 m walk/run test),
30SSS (30 sec sit and stand test), 9HPT (nine-hole peg test), SARA (scale for assessment and rating of ataxia), and QMT: quantitative muscle test-
ing (best score of three). BMI, body mass index.
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gave hints of improvement. When assessing the adult pheno-
type subgroup independently, some QMT scores showed sig-
nificant improvement from baseline (T1) to follow-up (T2)
(Table 4); and some participants classified with a MIRS IV at
T1 escalated up to a MIRS II at T2 (Fig. 3). Even though this
is a progressive disease and it would be unlikely to detect
improvement when there has been no intervention, we cannot
accept or reject these findings as multiple factors could influ-
ence on muscle strength scoring from T1 to T2. Other studies
that have investigated natural disease progression in DM1
over a longer period of time,16,31 identified differences in
speed and magnitude of disease progression between the late
onset and the adult phenotype. These differences were not
detected at our 1-year study.
This study has several limitations. First, all assessments
tested in this study have been completed on a 1-day visit.
Having two independent visits closer in time (1 day or
1 week apart) or having two independent assessors
repeating the examinations would have inform conclu-
sions regarding validity and standard error of measure-
ment. Secondly, this study does not address other factors
that could influence in performance such as: physical
activity levels, myotonia, fatigability, and co-morbidities.
Additionally, this study has been completed at two differ-
ent sites involving seven trained assessors (three of which
over 80% of the assessments), which may impact on the
variability observed in the muscle strength scores (includ-
ing MIRS). Lastly, even though the overall sample is one
of the largest studied to date in DM1, a rare disease, it,
did not have sufficient statistical power to allow for sub-
group comparisons.
Based on the lessons learned from this study, the
authors have highlighted the points below for considera-
tion when including any of these tests as outcomes in
clinical trials or research studies in DM1:
• Follow OMMYD methodological references when
selecting an outcome and methodology suitable for
DM1 adults.25 *Variants from these guidelines applied
in this study: flying start allowed for the 10mWT and
the 10mW/RT.
• Correct for BMI and disease severity (i.e., MIRS) when
comparing groups.
• Stratify your sample based on disease phenotype and
sex if possible.
• Perform at least two trials for any of the selected
FCOM to prevent bias from learning effect and include
the best of these for your analysis.
• Although not capturing walking endurance as the
6MWT, the 10mWT, and 10mW/RT reflect similar func-
tional walking capacity making them feasible alternatives
to implement in clinical trials allowing trial repetition
and the need of relatively shorter testing-time and space.
I II III IV V
MIRS I (T1) MIRS II (T1) MIRS III (T1) MIRS IV (T1) MIRS V (T1)
MIRS score  at T2
MIRS score changes from T1 (baseline) to T2 (follow-up)
Figure 3. Muscular Impairment Rating Scale (MIRS) changes from baseline (T1) to follow-up (T2). This bar chart presents the whole sample
classified based on the MIRS score assigned at baseline (T1) and differentiated in gray scale based on their MIRS score assigned at follow-up (T2).
The width of each column has been defined based on the amount of patients on each T1-MIRS group.
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• A repetitive 30SSS test may add information about
other disease symptoms impacting on test performance
such as balance and fatigue.
Conclusion
This study reports the first full exploration of five FCOM
tests (6MWT, 10mWT, the 10mW/RT, the 30SSS, and the
9HPT) in adults with genetically and phenotypically
determined DM1 as recommended by the OMMYD
group.46 The large sample size and the standardized
methodology followed allow these results to be considered
as appropriate reference values for future clinical trials.
Overall, this study has defined suitable methodology for
future studies assessing interventions offering improve-
ment in DM1 patients’ functional capacity.
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